Connection

Idris Guessous to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Idris Guessous has written about Antibodies, Viral.
Idris Guessous
Connection Strength
0.289
Antibodies, Viral
  1. Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nat Commun. 2021 06 08; 12(1):3455.
    View in: PubMed
    Score: 0.090
  2. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 08 01; 396(10247):313-319.
    View in: PubMed
    Score: 0.084
  3. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Eur J Clin Invest. 2021 Nov; 51(11):e13661.
    View in: PubMed
    Score: 0.023
  4. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov; 27(11):1695.e7-1695.e12.
    View in: PubMed
    Score: 0.023
  5. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health. 2020 Dec; 65(9):1529-1548.
    View in: PubMed
    Score: 0.022
  6. Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. Eur J Clin Invest. 2020 Oct; 50(10):e13357.
    View in: PubMed
    Score: 0.021
  7. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020 Oct; 26(10):1386-1394.
    View in: PubMed
    Score: 0.021
  8. Perceptions of immunity and vaccination certificates among the general population: a nested study within a serosurvey of anti-SARS-CoV-2 antibodies (SEROCoV-POP). Swiss Med Wkly. 2020 11 16; 150:w20398.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.